Disease Info Card

Leiomyoma, Multiple Cutaneous

Information about Leiomyoma, Multiple Cutaneous: characteristics, related genes and pathways, plus antibodies you can use for research. This page is being enriched constantly, if you see some information you would like this page to include please send your suggestions to us.

Overview of Leiomyoma, Multiple Cutaneous

Most recent studies have shown that Leiomyoma, Multiple Cutaneous shares some biological mechanisms with benign-neoplasm, carcinoma, cutaneous-leiomyoma, dermatologic-disorders, fibroid-tumor, hereditary-diseases, hereditary-leiomyomatosis-and-renal-cell-cancer, kidney-neoplasm, leiomyomatosis, malignant-neoplasm-of-kidney, malignant-neoplasms, myoma, neoplasms, neoplasms-multiple-primary, neoplastic-syndromes-hereditary, pathologic-neovascularization, renal-cell-carcinoma, skin-neoplasms, uterine-fibroids, uterine-neoplasms.

Among the many pathways, these few ones have gauged particular interests from scientists studying Leiomyoma, Multiple Cutaneous, and have been seen in publications frequently: Angiogenesis, Glucose Transport, Glycolysis, Methylation, Mismatch Repair, Response To Cold, Transport

Quite a number of genes have been found to play important roles in Leiomyoma, Multiple Cutaneous, such as CFH, CHML, EXO1, FH, FHIT, HIF1A, KMO, LDLR, MET, MLH1, MSH2, OPN3, RASSF1, RGS7, SETD2, TWSG1, VHL. See what Boster has to offer for the research of these genes by clicking the gene name links below and view a more detailed info card/product listing for that gene.

In a later update, we will include information such as current drugs and therapy solutions as well as on-going and past clinical trials for this disease. Plesae stay updated.